Korro Bio (KRRO) grants SVP Finance Dolan Oliver 15,000 stock options

Rhea-AI Filing Summary

Korro Bio, Inc. reported that Senior Vice President of Finance Dolan Oliver received a stock option award. On February 2, 2026, Oliver was granted an option to buy 15,000 shares of Korro Bio common stock at an exercise price of $13.05 per share, expiring February 1, 2036.

The option vests in 48 equal monthly installments starting February 2, 2026, contingent on Oliver’s continued service with the company on each vesting date. After this grant, Oliver beneficially owns 15,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dolan Oliver

(Last) (First) (Middle)

C/O KORRO BIO, INC.

60 FIRST STREET, 2ND FLOOR, SUITE 250

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.05	02/02/2026		A		15,000		(1)	02/01/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. The shares subject to the option vest in 48 equal monthly installments commencing from February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Jeffrey Cerio, Attorney-in-fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Korro Bio (KRRO) report for Dolan Oliver?

Korro Bio reported that Senior Vice President of Finance Dolan Oliver received a stock option grant for 15,000 shares. The option was awarded on February 2, 2026 and gives him the right to purchase Korro Bio common stock at a fixed exercise price over time.

How many Korro Bio stock options were granted to Dolan Oliver and at what price?

Dolan Oliver was granted stock options covering 15,000 shares of Korro Bio common stock at an exercise price of $13.05 per share. These options were issued as a single award and represent derivative securities directly beneficially owned by him after the reported transaction.

When do Dolan Oliver’s Korro Bio options vest and over what period?

The options vest in 48 equal monthly installments beginning February 2, 2026. Each month, a portion of the 15,000-share grant becomes exercisable, provided Oliver continues serving the company on each vesting date, effectively spreading vesting over a four-year period from the start date.

What is the expiration date of Dolan Oliver’s Korro Bio stock options?

Dolan Oliver’s stock options expire on February 1, 2036. This gives him a multi-year window, after vesting, to exercise the options at the fixed $13.05 exercise price, so long as standard service and plan conditions applicable to the award continue to be satisfied.

What is Dolan Oliver’s beneficial ownership in Korro Bio derivative securities after this grant?

Following the transaction, Dolan Oliver beneficially owns 15,000 derivative securities in Korro Bio directly. These derivative securities represent the stock options granted on February 2, 2026, all tied to the right to purchase an equal number of shares of common stock upon exercise.